WO1998008463A1 - Dispositifs medicaux presentant des caracteristiques de matieres resistantes aux microbes - Google Patents

Dispositifs medicaux presentant des caracteristiques de matieres resistantes aux microbes Download PDF

Info

Publication number
WO1998008463A1
WO1998008463A1 PCT/US1997/015011 US9715011W WO9808463A1 WO 1998008463 A1 WO1998008463 A1 WO 1998008463A1 US 9715011 W US9715011 W US 9715011W WO 9808463 A1 WO9808463 A1 WO 9808463A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical device
prosthesis
polymers
organisms
micro
Prior art date
Application number
PCT/US1997/015011
Other languages
English (en)
Inventor
Stephen W. Laguette
Thomas M. Vassallo
Edmund V. Seder
Original Assignee
Helix Medical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Medical Corporation filed Critical Helix Medical Corporation
Priority to AU40909/97A priority Critical patent/AU4090997A/en
Publication of WO1998008463A1 publication Critical patent/WO1998008463A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/20—Epiglottis; Larynxes; Tracheae combined with larynxes or for use therewith
    • A61F2/203—Epiglottis; Larynxes; Tracheae combined with larynxes or for use therewith comprising an air passage from trachea to oesophagus or to pharynx; Artificial epiglottis

Definitions

  • the present invention relates to microbial-resistant medical devices and, more particularly, this invention relates to a voice prosthesis having material properties which resist growth of microbial organisms.
  • Medical devices particularly prosthetic devices which are used in environments where micro-organisms such as fungi or yeast are actively growing, can become covered with a microbial layer to the point where the function of the device is impaired. The fouled device must be cleaned or discarded.
  • a trachea voice prosthesis containing a one-way valve such as a BLOM-SINGER ® voice prosthesis is inserted into the tracheoesophageal fistula.
  • the one-way valve protects the airway during swallowing but opens under positive pressure.
  • the voice prosthesis thus, permits a patient to divert air from the lungs into the esophagus and out through the mouth. Speech is created during passage of air through the upper part of the esophagus .
  • the prosthesis maintains the fistula open, transfers air from the trachea to the esophagus for voice production and prevents esophageal leakage into the trachea during swallowing.
  • the oral cavity which extends into the throat has a high microbial population.
  • the prosthesis being in contact with moisture in a hot, dark environment is subject to growth of commonly found micro-organisms, typically Candida Albicans on the valve and the retaining flange.
  • the microbial attack is currently being studied. The microbial attack, organisms and sequence of events are quite complex and are still undetermined. The microbial growth can interfere with function of the valve and can cause the flange to wrinkle and leak.
  • the current low pressure voice prosthesis can be removed by the patient every few days and can be replaced with a clean prosthesis.
  • the removed prosthesis is soaked in hydrogen peroxide to remove the layer of yeast from the valve and flange.
  • a longer dwelling, low pressure voice prosthesis has been developed that can remain in place in the tracheoesophageal fistula for many weeks or months, depending on the patient and conditions of use. The patient can confidently use the prosthesis for longer periods.
  • the longer dwelling voice prosthesis is not removable by the patient and does not allow cleaning and soaking. Trips to a health care specialist to remove and replace the prosthesis are greatly extended providing increased comfort and lower cost to the patient.
  • Microbial growth on the valve can also cause distortion of the shape of the valve or form wrinkles in the body of the valve which prevents the valve from closing. Leaking also ap- pears to be due to distortion of the valve body adjacent to the seat of the valve and to yeast growth on the seat. Forming the valve with an arcuate dome shape increased resistance to folding or bending of the valve. However, some valves still leaked after extended placement in a fistula.
  • Margraf discloses the use of a silver-heparin-allantoin complex to a form non-thrombogenic, self sterilizing surface on prosthetic valves or arterial grafts.
  • the complex can be coated or impregnated into the surface of the valve or graft .
  • Crossley coats the surface of an urinary tract catheter with Ag or Ag compounds by dispersing silver or its compound in resin. The surface is abraded to expose the silver material.
  • the coating contains 10% by weight of silver (col 4, line 10) .
  • the coating can be extremely thin such as those deposited by electroless deposition (col 4, lines 16-18).
  • Fox, Jr. et al . , 4,563,485 discloses use of silver norfloxacin or silver perfloxacin to render muscular graft prosthesis formed from resins such as silicone infection resistan .
  • Fox, Jr. et al . , 4,581,028 utilizes silver metal salts of sulfonamides or other antimicrobials for the same purpose.
  • Fox, Jr. et al . , 4,612,337 discloses and claims a method of preparing an infection resistant material by solvent impregnation of the material with a silver salt and another compound and reaction in situ to form a silver salt .
  • Scales et al . , 4,615,705 provides a bioerodible silver coating on the surface of endoprosthetic orthopaedic implants to render the surface antimicrobial.
  • Fox, Jr. et al . , 5,019,096 discloses the use of a complex of a silver salt and chlorhexidine to add antimicrobial properties to biomedical polymers such as silicones.
  • Dorland's Illustrated Medical Dictionary discloses the use of silver picrate to locally treat monilia (Candida) in- fections of the vagina.
  • U.S. Patent No. 5,314,470 discloses a soft voice prosthesis which includes a stiffening ring 14 inserted into a groove in the body of the prosthesis. Though the ring stiffens the body adjacent the valve it does not prevent distor- tion of the body by muscular movement or distortion of the valve by growth of yeast .
  • the invention relates to the discovery of a polymer material that can be used to form the microbial resistant properties for medical devices, especially prosthetic devices exposed to Candida Albicans in oral and tracheal environments.
  • the material is safe and effective and is neither toxic, inflammatory nor irritating to adjacent tissues.
  • the material can be plastic or elastomeric, as required, depending on compounding.
  • Preferred materials are liquid polymers that can be cast or molded or thermoplastic polymers that can be softened to be shaped by molding or extrusion.
  • the microbial resistant materials of the invention are formed from polymers containing a plurality of fluorine atoms pendant from the polymer backbone.
  • the polymer material can have a carbon backbone or a siloxane backbone.
  • the fluorine atoms can be directly attached to the polymer backbone or can be attached to a group pendant from the backbone such as a group containing 1 to 20 carbon atoms, suitably an alkyl group, aryl group, cycloakyl group or combinations thereof.
  • the polymer of the invention can contain segments of other polymers or can be mixed with other polymers to modify or adjust properties.
  • the mechanism for inhibiting growth of yeast is not understood though it is believed to be a function of the smoothness and inertness of the surface of these polymers inhibiting attachment and growth of a colony of yeast cells.
  • the fluorine atom may also exhibit toxicity to the yeast cells and contributes inertness to the polymer.
  • the polymer contains at least 0.1% by weight of fluorine in the polymer, preferably from 1 to 10% by weight.
  • fluorine-containing polymers are fluorocarbon, fluorinated silicone polymers and fluorinated acrylate polymers. Silicone based materials are preferred since they are more processable to form a prosthesis with elastomeric properties. Silastic fluorosilicones are known to have good resistance to acids, alkalis, solvents, oils, alcohols, esters and ketones. Fluoralkyl substituted silicones have shown the best yeast resistance to date. Further testing of trifluoro-alkyl substituted siloxanes is proceeding.
  • Figure 1 is a schematic view of a voice prosthesis installed in a tracheoesophageal fistula
  • Figure 2 is a partial view in section of a voice prosthesis with hinged valve
  • Figure 3 is a view in section of a voice prosthesis con- taining an internal rigid cartridge; and Figure 3A is an enlarged sectional view of a portion of Figure 3 for purposes of clarity.
  • the invention will be illustrated by a long-dwelling voice prosthesis, though it is applicable to any prosthetic or medical device disposed in a body cavity having an environment conducive to growth of micro-organisms such as Candida Al- bicans .
  • a voice prosthesis 10 is shown inserted into a fistula 62 with the front flange 14 engaging the outer wall 64 of the trachea and the rear flange 16 engaging the wall 66 of the esophagus.
  • the body 12 of the pros- thesis 10 prevents the fistula 62 from closing.
  • the prosthesis also contains a valve 60 as shown in Figure 2.
  • the valve 60 is preferably separately molded and has a flap which is attached to the prosthesis 10.
  • the valve 60 contains radiopaque pigment and the flange 14 may contain a radiopaque ring 50 for visualization of the valve 60 and concentric ring 50 after the prosthetic device has been seated in the fistula as disclosed in U.S. Patent No. 5,480,432, the disclosure of which is expressly incorporated herein by reference.
  • At least the valve 60 is formed of the yeast resistant material of the invention or contains a thin coating 63 formed on the surface of the valve 60.
  • the prosthesis 10 can further contain an internal, rigid cartridge 18 to reinforce the body of the soft prosthesis as shown in Figures 3 and 3A and as disclosed in copending ap- plication Serial No. 08/559,210 filed November 13, 1995, the disclosure of which is expressly incorporated herein by reference .
  • the voice prosthesis 90 contains an improved cartridge 92.
  • the front flange 94 of the cartridge 92 has a bevel 96 so that it is easier to move the front flange 94 past the boss 98 on the body 100 of the device.
  • a groove 102 may be provided in the inner wall 101 of the body 100 adjacent the front of the boss 98.
  • the groove 102 preferably has a beveled front face to receive and lock the flange 94 as it snaps into the groove 102.
  • the boss 98 seats between the flanges 94 and 110 and the wall segment 139 of the cartridge 92.
  • Another feature of the cartridge 92 of the invention is the placement of the adhesive cavity 106 in the rear of the rear flange 110 such that it communicates with the slot 112.
  • the valve 15 and cartridge 92 can be preassembled before the cartridge is inserted into the flexible body 100.
  • the tab 56 is inserted through slot 112 in the flange 110 into the cavity 106.
  • Adhesive 70 can be placed into the cavity from the rear opening 113 of the cavity 106. There is no need for a cavity in the flexible body which would weaken the body and could provide a site for failure during flexure of the soft elastic body adjacent the hard flange.
  • the body 100 can also contain an elongated hood 120 placed rearward of the rear flange 110 to further protect the valve 15 from failing.
  • the microbial resistant surface of the invention may eliminate or reduce the need to utilize a thick domed valve and a thicker, stiffer rear flange. Since the growth of a thick layer of yeast will be inhibited, warping of the valve is reduced or eliminated.
  • the microbial resistant surface can be provided by coating or laminating a layer of yeast resistant polymer onto the exposed surfaces of the valve and body of the prosthesis.
  • the microbial resistant surface is formed of a polymer having a minimum thickness to inhibit microbial growth, generally at least 0.005 inches in thickness and usually from 0.01 to 0.3 inches in thickness.
  • a layer of microbial resistant polymer can be coated onto the surface from solutions or dispersions of the polymer, can be formed on the surface by polymerization of monomers in situ, or by curing liquid prepoly ers on the surface of the prosthesis.
  • the layers can also be laminated to the surface by adhesive or by heat.
  • the prosthesis may be formed from the microbial resistant polymer.
  • Suitable fluorocarbon polymers for forming the yeast resistant surface are high fluorine content fluorocarbons in which at least 20% of the chain carbon atoms are substituted with fluorine.
  • Representative commercially available polymers are polytetrafluoroethylene , chlorotriflouroethylene , polyvinylidene fluoride, and copolymers such as copolymer of chlortrifluoroethylene and vinylidene fluoride, copolymer of hexafluoropropylene and vinylidene fluoride, perfluoro butyl acrylate .
  • Voice prosthesis are usually formed from elastomers in order to better conform to and seal the device in a fistula.
  • a preferred class of fluorinated elastomer are based on fluoroalkyl substituted siloxanes having a repeating unit of the formula: R 1
  • R 1 is a group containing 1 to 10 carbon atoms such as alkyl, suitably methyl, aryl such as phenyl or aralkyl, alkaryl
  • R 2 is a divalent group containing 1 to 8 carbon atoms such as ethylene
  • the molecular weight can be from 20,000 to 5,000,000, generally from 50,000 to 1,000,000. Replacement of the methyl group with a longer alkyl chain modifies the properties of the siloxanes.
  • the activation energy for viscous flow and the rate of change of viscosity with temperature and pressure increase.
  • Methyl trifluoropropyl silicone has a solubility parameter of about 9.5 compared to about 7.5 for dimethyl silicone.
  • a commercially available fluorosilicone elastomer is methyl trifluoropropyl siloxane having the following physical properties suitable for a voice prosthesis .
  • Fluorosilicone raw gums can be prepared from anionic, non-solvent reactions of the corresponding cyclosiloxanes .
  • the fluorosilicone elastomers are generally polymerized by free radical initiated polymerization using free radical agents such as benzoyl peroxide or bis (2, 4 - dichlorobenzoyl) peroxide .
  • Compression molding is the most widely used method and is ideal for a great many fabrications at temperatures between 116-171° C and pressure of MPa 5.5-10.3 (psi 800-1500).
  • In- jection molding is becoming increasingly important for high production operations and generally requires higher temperatures and pressures then compression molding.
  • Transfer molding is particularly useful for molding complex parts in multicavity presses. Since corrosive gases are not liberated during the molding process, a variety of metals such as brass, steel, copper, stainless steel, etc. can be used in making the mold. Where dimensional accuracy of molded parts is very important the design of the mold must allow for shrinkage of the parts. Linear shrinkage of most fluorosilicones is 2.5-3.5%.
  • a clinical trial (in vivo) was conducted to determine the effectiveness of fluorosilicone resins such as methyl trifluoropropyl siloxane in inhibiting microbial growth and prolonging the useful life of a voice prosthesis.
  • the trail is still in progress with additional patients being added as available .
  • Voice prosthesis formed with microbial resistant polymer surfaces will be able to be used for much longer periods without the need to remove the prosthesis for cleaning.
  • the prosthesis can be made with thinner valves, body and flanges since there is no need to be as stiff and rigid to avoid bending and wrinkling due to growth of Candida Albicans or other microorganisms.

Abstract

On inhibe la croissance microbienne à la surface d'un dispositif médical tel qu'une prothèse, et notamment une prothèse vocale (10) en fabriquant ladite prothèse ou en disposant à sa surface une couche d'un fluoropolymère sélectionné parmi un polymère fluorocarboné et un polymère de fluorosilicone, notamment un siloxane substitué par un perfluoroalkyle tel que le siloxane de méthyl-trifluoropropyle.
PCT/US1997/015011 1996-08-30 1997-08-26 Dispositifs medicaux presentant des caracteristiques de matieres resistantes aux microbes WO1998008463A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40909/97A AU4090997A (en) 1996-08-30 1997-08-26 Medical devices having microbial resistant material properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70633196A 1996-08-30 1996-08-30
US08/706,331 1996-08-30

Publications (1)

Publication Number Publication Date
WO1998008463A1 true WO1998008463A1 (fr) 1998-03-05

Family

ID=24837107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015011 WO1998008463A1 (fr) 1996-08-30 1997-08-26 Dispositifs medicaux presentant des caracteristiques de matieres resistantes aux microbes

Country Status (2)

Country Link
AU (1) AU4090997A (fr)
WO (1) WO1998008463A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192957A2 (fr) * 2000-09-29 2002-04-03 Ethicon, Inc. Revêtement pour dispositifs médicaux
WO2002026280A1 (fr) * 2000-09-29 2002-04-04 Ethicon, Inc. Revêtements destinés à des dispositifs médicaux
WO2002026281A1 (fr) * 2000-09-29 2002-04-04 Cordis Corporation Dispositifs medicaux avec enrobages
EP1707156A1 (fr) * 2005-03-29 2006-10-04 Helix Medical Inc. Prothèse vocale ayant des propriétés antimicrobiennes
US20060287722A1 (en) * 2005-06-17 2006-12-21 Helix Medical Products, Inc. Voice Prosthesis Device
EP1762255A1 (fr) * 2000-09-29 2007-03-14 Cordis Corporation Dispositifs médicaux revêtus
US7393547B2 (en) 2001-04-11 2008-07-01 Helix Medical, Llc Antimicrobial elastomer composition and method for making
US7520897B2 (en) * 2001-04-11 2009-04-21 Helix Medical, Llc Medical devices having antimicrobial properties
US7645504B1 (en) 2003-06-26 2010-01-12 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
US8097268B2 (en) 2003-05-01 2012-01-17 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US8871883B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible coating for implantable medical devices
US8871236B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8883175B2 (en) 2003-11-14 2014-11-11 Abbott Cardiovascular Systems Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
WO2015041695A1 (fr) * 2013-09-23 2015-03-26 Creighton University Dispositif prothétique et revêtement associé
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US9067000B2 (en) 2004-10-27 2015-06-30 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US9084671B2 (en) 2002-06-21 2015-07-21 Advanced Cardiovascular Systems, Inc. Methods of forming a micronized peptide coated stent
US9101697B2 (en) 2004-04-30 2015-08-11 Abbott Cardiovascular Systems Inc. Hyaluronic acid based copolymers
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9175162B2 (en) 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives
US9339592B2 (en) 2004-12-22 2016-05-17 Abbott Cardiovascular Systems Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US9364498B2 (en) 2004-06-18 2016-06-14 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US9580558B2 (en) 2004-07-30 2017-02-28 Abbott Cardiovascular Systems Inc. Polymers containing siloxane monomers
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304010A (en) * 1978-10-12 1981-12-08 Sumitomo Electric Industries, Ltd. Tubular polytetrafluoroethylene prosthesis with porous elastomer coating
US5529820A (en) * 1993-03-17 1996-06-25 Japan Gore-Tex, Inc. Flexible, non-porous tube and a method of making

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304010A (en) * 1978-10-12 1981-12-08 Sumitomo Electric Industries, Ltd. Tubular polytetrafluoroethylene prosthesis with porous elastomer coating
US5529820A (en) * 1993-03-17 1996-06-25 Japan Gore-Tex, Inc. Flexible, non-porous tube and a method of making

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1764120A1 (fr) * 2000-09-29 2007-03-21 Ethicon, Inc. Revêtement pour dispositifs médicaux
WO2002026280A1 (fr) * 2000-09-29 2002-04-04 Ethicon, Inc. Revêtements destinés à des dispositifs médicaux
WO2002026281A1 (fr) * 2000-09-29 2002-04-04 Cordis Corporation Dispositifs medicaux avec enrobages
EP1192957A3 (fr) * 2000-09-29 2004-02-18 Ethicon, Inc. Revêtement pour dispositifs médicaux
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
AU2001293161B2 (en) * 2000-09-29 2005-03-24 Ethicon, Inc. Coatings for medical devices
EP2848265A3 (fr) * 2000-09-29 2015-09-02 Ethicon, Inc. Revêtements pour matériel médical
EP1762255A1 (fr) * 2000-09-29 2007-03-14 Cordis Corporation Dispositifs médicaux revêtus
EP1192957A2 (fr) * 2000-09-29 2002-04-03 Ethicon, Inc. Revêtement pour dispositifs médicaux
US8317861B2 (en) * 2001-04-11 2012-11-27 Helix Medical, Llc Antimicrobial indwelling voice prosthesis
US7393547B2 (en) 2001-04-11 2008-07-01 Helix Medical, Llc Antimicrobial elastomer composition and method for making
US7520897B2 (en) * 2001-04-11 2009-04-21 Helix Medical, Llc Medical devices having antimicrobial properties
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US9084671B2 (en) 2002-06-21 2015-07-21 Advanced Cardiovascular Systems, Inc. Methods of forming a micronized peptide coated stent
US8871236B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8986726B2 (en) 2002-12-11 2015-03-24 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8871883B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible coating for implantable medical devices
US8097268B2 (en) 2003-05-01 2012-01-17 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US8367091B2 (en) 2003-05-01 2013-02-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US9175162B2 (en) 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives
US7645504B1 (en) 2003-06-26 2010-01-12 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers
US8883175B2 (en) 2003-11-14 2014-11-11 Abbott Cardiovascular Systems Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US9446173B2 (en) 2003-11-14 2016-09-20 Abbott Cardiovascular Systems Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9101697B2 (en) 2004-04-30 2015-08-11 Abbott Cardiovascular Systems Inc. Hyaluronic acid based copolymers
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US9364498B2 (en) 2004-06-18 2016-06-14 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9375445B2 (en) 2004-06-18 2016-06-28 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9580558B2 (en) 2004-07-30 2017-02-28 Abbott Cardiovascular Systems Inc. Polymers containing siloxane monomers
US9067000B2 (en) 2004-10-27 2015-06-30 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US9339592B2 (en) 2004-12-22 2016-05-17 Abbott Cardiovascular Systems Inc. Polymers of fluorinated monomers and hydrocarbon monomers
AU2006200415B2 (en) * 2005-03-29 2008-10-16 Helix Medical, Llc Antimicrobial indwelling voice prosthesis
EP1707156A1 (fr) * 2005-03-29 2006-10-04 Helix Medical Inc. Prothèse vocale ayant des propriétés antimicrobiennes
US20060287722A1 (en) * 2005-06-17 2006-12-21 Helix Medical Products, Inc. Voice Prosthesis Device
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
WO2015041695A1 (fr) * 2013-09-23 2015-03-26 Creighton University Dispositif prothétique et revêtement associé

Also Published As

Publication number Publication date
AU4090997A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998008463A1 (fr) Dispositifs medicaux presentant des caracteristiques de matieres resistantes aux microbes
US20020193879A1 (en) Medical devices having antimicrobial properties
AU715502B2 (en) Biostable elastomeric polymers having quaternary carbons
US9314548B2 (en) Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
CA1252253A (fr) Implant mammaire
CN102947237A (zh) 抗微生物剂涂覆的医学制品
CA1324545C (fr) Instrument medical et methode de fabrication de ce dernier
US20090026660A1 (en) Methods of making antimicrobial voice prothesis devices
US7520897B2 (en) Medical devices having antimicrobial properties
US5224958A (en) Silicone elastomer line prosthetic devices and methods of manufacture
EP1786413B1 (fr) Composition élastomère antimicrobienne et procédé de fabrication
US4251215A (en) Phosphonitrilic fluoroelastomer lined denture
WO1999044665A2 (fr) Instrument medical utilisant des materiaux d'hydrogel
KR20010040354A (ko) 전도성, 비정질 비점착성 코팅 제공방법 및 장치
CN1299382A (zh) 含聚硅氧烷的聚氨酯弹性体组合物
JP6793207B2 (ja) 医療用潤滑性部材、これを用いた医療機器、及び医療用潤滑性部材の製造方法
US11826493B2 (en) Antimicrobial coatings for medical implements and medical devices
McMillin Elastomers for biomedical applications
US5112640A (en) Silicone elastomer lined prosthetic devices and methods of manufacture
US7411029B2 (en) Prepolymers for improved surface modification of contact lenses
Boretos et al. Biomedical elastomers
Chauvel-Lebret et al. Biocompatibility of elastomers
Petraitis Silicone biomaterials
Chauvel-Lebret et al. Biocompatibility of elastomers
JPS61161207A (ja) ポリウレタンエラストマー製義歯床用コート材

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511846

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA